172 related articles for article (PubMed ID: 28232658)
1. [Therapeutic development for GNE myopathy.].
Suzuki N; Izumi R; Kato M; Warita H; Aoki M
Clin Calcium; 2017; 27(3):429-434. PubMed ID: 28232658
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of Aceneuramic Acid for Distal Myopathy with Rimmed Vacuoles].
Aoki M; Izumi R; Suzuki N
Brain Nerve; 2023 Oct; 75(10):1149-1154. PubMed ID: 37849366
[TBL] [Abstract][Full Text] [Related]
3. [Sialic Acid Replacement Therapy for Distal Myopathy with Rimmed Vacuoles].
Mori-Yoshimura M; Nishino I
Brain Nerve; 2015 Sep; 67(9):1115-23. PubMed ID: 26329152
[TBL] [Abstract][Full Text] [Related]
4. Sialyllactose ameliorates myopathic phenotypes in symptomatic GNE myopathy model mice.
Yonekawa T; Malicdan MC; Cho A; Hayashi YK; Nonaka I; Mine T; Yamamoto T; Nishino I; Noguchi S
Brain; 2014 Oct; 137(Pt 10):2670-9. PubMed ID: 25062695
[TBL] [Abstract][Full Text] [Related]
5. GNE myopathy: from clinics and genetics to pathology and research strategies.
Pogoryelova O; González Coraspe JA; Nikolenko N; Lochmüller H; Roos A
Orphanet J Rare Dis; 2018 May; 13(1):70. PubMed ID: 29720219
[TBL] [Abstract][Full Text] [Related]
6. Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathy.
Xu X; Wang AQ; Latham LL; Celeste F; Ciccone C; Malicdan MC; Goldspiel B; Terse P; Cradock J; Yang N; Yorke S; McKew JC; Gahl WA; Huizing M; Carrillo N
Mol Genet Metab; 2017 Sep; 122(1-2):126-134. PubMed ID: 28641925
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in establishing a cure for GNE myopathy.
Yoshioka W; Nishino I; Noguchi S
Curr Opin Neurol; 2022 Oct; 35(5):629-636. PubMed ID: 35959526
[TBL] [Abstract][Full Text] [Related]
8. [GNE myopathy: proven failure of sialic acid supplementation… what's next?].
Marion S; Béhin A; Attarian S
Med Sci (Paris); 2017 Nov; 33 Hors série n°1():55-56. PubMed ID: 29139388
[No Abstract] [Full Text] [Related]
9. [Sialic acid supplementation therapy for distal myopathy with rimmed vacuoles (GNE myopathy)].
Nishino I; Noguchi S
Rinsho Shinkeigaku; 2012; 52(11):1210-2. PubMed ID: 23196566
[TBL] [Abstract][Full Text] [Related]
10. Understanding pathophysiology of GNE myopathy and current progress towards drug development.
Mashangva F; Singh S; Oswalia J; Arya R
J Biosci; 2024; 49():. PubMed ID: 38383974
[TBL] [Abstract][Full Text] [Related]
11. Efficacy confirmation study of aceneuramic acid administration for GNE myopathy in Japan.
Mori-Yoshimura M; Suzuki N; Katsuno M; Takahashi MP; Yamashita S; Oya Y; Hashizume A; Yamada S; Nakamori M; Izumi R; Kato M; Warita H; Tateyama M; Kuroda H; Asada R; Yamaguchi T; Nishino I; Aoki M
Orphanet J Rare Dis; 2023 Aug; 18(1):241. PubMed ID: 37568154
[TBL] [Abstract][Full Text] [Related]
12. A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy.
Lochmüller H; Behin A; Caraco Y; Lau H; Mirabella M; Tournev I; Tarnopolsky M; Pogoryelova O; Woods C; Lai A; Shah J; Koutsoukos T; Skrinar A; Mansbach H; Kakkis E; Mozaffar T
Neurology; 2019 Apr; 92(18):e2109-e2117. PubMed ID: 31036580
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and clinical efficacy of 6'-sialyllactose in patients with GNE myopathy: Randomized pilot trial.
Park YE; Park E; Choi J; Go H; Park DB; Kim MY; Sung NJ; Kim L; Shin JH
Biomed Pharmacother; 2023 Dec; 168():115689. PubMed ID: 37852099
[TBL] [Abstract][Full Text] [Related]
14. [Sialic Acid supplementation therapy for distal myopathy with rimmed vacuoles].
Nishino I; Noguchi S
Brain Nerve; 2012 Mar; 64(3):255-61. PubMed ID: 22402719
[TBL] [Abstract][Full Text] [Related]
15. Phase II/III Study of Aceneuramic Acid Administration for GNE Myopathy in Japan.
Suzuki N; Mori-Yoshimura M; Katsuno M; Takahashi MP; Yamashita S; Oya Y; Hashizume A; Yamada S; Nakamori M; Izumi R; Kato M; Warita H; Tateyama M; Kuroda H; Asada R; Yamaguchi T; Nishino I; Aoki M
J Neuromuscul Dis; 2023; 10(4):555-566. PubMed ID: 37125562
[TBL] [Abstract][Full Text] [Related]
16. Sialic acid deficiency is associated with oxidative stress leading to muscle atrophy and weakness in GNE myopathy.
Cho A; Christine M; Malicdan V; Miyakawa M; Nonaka I; Nishino I; Noguchi S
Hum Mol Genet; 2017 Aug; 26(16):3081-3093. PubMed ID: 28505249
[TBL] [Abstract][Full Text] [Related]
17. Aceneuramic Acid Extended Release Administration Maintains Upper Limb Muscle Strength in a 48-week Study of Subjects with GNE Myopathy: Results from a Phase 2, Randomized, Controlled Study.
Argov Z; Caraco Y; Lau H; Pestronk A; Shieh PB; Skrinar A; Koutsoukos T; Ahmed R; Martinisi J; Kakkis E
J Neuromuscul Dis; 2016 Mar; 3(1):49-66. PubMed ID: 27854209
[TBL] [Abstract][Full Text] [Related]
18. [Animal model of distal myopathy with rimmed vacuoles/hereditary inclusion body myopathy and preclinical trial with sugar compounds].
Noguchi S; Malicdan MC; Nishino I
Brain Nerve; 2010 Jun; 62(6):601-7. PubMed ID: 20548120
[TBL] [Abstract][Full Text] [Related]
19. [GNE myopathy].
Urtizberea JA; Béhin A
Med Sci (Paris); 2015 Nov; 31 Spec No 3():20-7. PubMed ID: 26546927
[TBL] [Abstract][Full Text] [Related]
20. Increased amyloid β-peptide uptake in skeletal muscle is induced by hyposialylation and may account for apoptosis in GNE myopathy.
Bosch-Morató M; Iriondo C; Guivernau B; Valls-Comamala V; Vidal N; Olivé M; Querfurth H; Muñoz FJ
Oncotarget; 2016 Mar; 7(12):13354-71. PubMed ID: 26968811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
